Displaying 161 - 170 of 1526
We are coming up on a critical moment to ensure Congress goes big and bold on health care this year. It's time to dial up the pressure and make sure that our health care…
Updated: 9/16/21 “Thursday 30” - Every Thursday at 12pm ET It's time to ramp up the pressure on our nation's leaders to ensure health and health care are prioritized in the next recovery package.…
Consumers First submitted comments to the Centers for Medicare and Medicaid Services on the CY 2022 Medicare Physician Fee Schedule proposed rule which sets the payment rates for how most physicians and paid throughout…
Families USA submitted this letter in response to CMS' request for comments on Tennessee's Section 1115 demonstration that was approved in the final days of the Trump Administration. Multiple elements of TennCare III are…
Congress is working to pass a vitally important budget reconciliation bill that would significantly lower health care costs, narrow racial and ethnic disparities in health and health care, and ensure everyone in America can…
As Congress works to develop a robust budget reconciliation package, now is the time to ensure the inclusion of legislation that advances health equity and improves the health of parents and their children. Families…
Virtual Roundtable: Taking Action to Lower Prescription Drug Costs As Congress returns this month to finalize the $3.5 billion reconciliation package, voters and stakeholders across New Jersey are urging Senator Bob Menendez to make…
On August 19, 2021, Families USA led over 75 national, state, and community organizations in thanking five key Senators who courageously filed an amendment that declared strong support for including Medicare negotiation within reconciliation…
As Congress continues to negotiate the inclusion of critical health provisions in the next recovery package, we must not lose sight of important regulations that the Biden Administration is working to finalize in the…
As Congress considers ways to reform drug pricing this year, it is, unsurprisingly, being met with heavy resistance from paid special interests, including pharmaceutical companies’ lawyers and lobbyists who claim that any attempt to…